Persistence with medication and overactive bladder: an ongoing challenge

References

• Abrams PH, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178.
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.
   PubMed Web of Science ®Google Scholar
• Jones C, Hill J, Chapple C. Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ. 2010;340:c2354.
   Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314; discussion 1314-1305.
   PubMed Web of Science ®Google Scholar
• Perry S, Shaw C, Assassa P, et al. An epidemiological study to establish the prevalence of urinary symptoms and felt need in the community: the Leicestershire MRC Incontinence Study. Leicestershire MRC Incontinence Study Team. J Public Health Med. 2000;22(3):427–434.
   PubMedGoogle Scholar
• Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Wein A, Nicholson S, et al. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–1033.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Clemens JQ, et al. The impact of OAB on physical activity in the United States: results from OAB-POLL. Urology. 2013;82(4):799–806.
   PubMed Web of Science ®Google Scholar
• Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367–374.
   PubMed Web of Science ®Google Scholar
• Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–18.
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Zuckerman IH, McNally D, et al. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009;15(4 Suppl):SS90–SS97.
   Google Scholar
• Lucas MG, Bosch RJ, Burkhard FC, et al. European Association of Urology guidelines on assessment and nonsurgical management of urinary incontinence. Actas Urol Esp. 2013;37(4):199–213.
   PubMed Web of Science ®Google Scholar
• Smith A, Bevan D, Douglas HR, et al. Management of urinary incontinence in women: a summary of NICE guidance BMJ 2013347; f51270.
   Google Scholar
• Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62(6):1040–1060.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.
   PubMed Web of Science ®Google Scholar
• Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98(5):1025–1032.
   PubMed Web of Science ®Google Scholar
• Dwyer P, Kelleher C, Young J, et al. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn. 2008;27(6):540–547.
   PubMed Web of Science ®Google Scholar
• Chodick G, Moser SS, Goldshtein I. Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):359–370.
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740.
   PubMed Web of Science ®Google Scholar
• Andy UU, Arya LA, Smith AL, et al. Is self-reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder? Neurourol Urodyn. 2015 May 20. doi:10.1002/nau.22798.
   Web of Science ®Google Scholar
• D’Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. JMCP. 2008;14(3):291–301.
   PubMed Web of Science ®Google Scholar
• Schabert VF, Bavendam T, Goldberg EL, et al. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15(4 Suppl):S118–S122.
   PubMedGoogle Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348(9024):383–386.
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–585.
   PubMed Web of Science ®Google Scholar
• Gomes T, Juurlink D, Mamdani M. Comparative adherence to oxybutynin or tolterodine among older patients. Eur J Clin Pharmacol. 2012;68(1):97–99.
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):17.67–17.74.
   Google Scholar
• Wagg A, Diles D, Berner T. Treatment patterns for patients on overactive bladder therapy: a retrospective statistical analysis using Canadian claims data. JHEOR. 2015;3:43–45.
   Google Scholar
• Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. Acta Obstet Gynecol Scand. 2013;92(10):1208–1215.
   PubMed Web of Science ®Google Scholar
• Shaya FT, Blume S, Gu A, et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care. 2005;11(4 Suppl):S121–S129.
   PubMed Web of Science ®Google Scholar
• Wagg A, Fahey A, Siddiqui E. Persistence with oral antimuscarinics used for the treatment of overactive bladder in different age groups of patients in general practice. Age and Ageing. 2010;39(suppl 1):i39–i40.
   Google Scholar
• Sicras-Mainar A, Rejas J, Navarro-Artieda R, et al. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J. 2014;25(4):485–492.
   PubMed Web of Science ®Google Scholar
• Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003–1012.
   PubMed Web of Science ®Google Scholar
• Linnér L, Schiöler H, Samuelsson E, et al. Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol. 2011;67(5):535–536.
   PubMed Web of Science ®Google Scholar
• Johnston S, Janning SW, Haas GP, et al. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes. Int J Clin Pract. 2012;66(11):1042–1051.
   PubMed Web of Science ®Google Scholar
• Krhut J, Gärtner M, Petzel M, et al. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients. Scand J Urol. 2014;48(1):79–83.
   PubMed Web of Science ®Google Scholar
• Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–350.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Hayes-Larson E, Sorg RA, et al. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder. J Med Econ. 2014;17(10):741–750.
   PubMedGoogle Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–1282.
   PubMed Web of Science ®Google Scholar
• Tarn DM, Heritage J, Paterniti DA, et al. Physician communication when prescribing new medications. Arch Intern Med. 2006;166(17):1855–1862.
   PubMedGoogle Scholar
• Lau HS, Beuning KS, Postma-Lim E, et al. Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharm World Sci. 1996;18(2):63–68.
   PubMed Web of Science ®Google Scholar
• Hjalmas K, Hellstrom A, Mogren K, et al. The overactive bladder in children: a potential future indication for tolterodine. BJU Int. 2001;87:569–574.
   PubMed Web of Science ®Google Scholar
• Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health. 2005;8(4):495–505.
   PubMed Web of Science ®Google Scholar
• DiMatteo M, Reite RR, Gambone J. Factors affecting medication adherence in Lebanese patients with chronic diseases. Pharm Pract (Granada). 2015;3(3):590.
   Google Scholar
• Rolnick SJ, Pawloski PA, Hedblom BD, et al. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54–65.
   PubMedGoogle Scholar
• Kennedy J, Morgan S. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 international health policy survey in seven countries. Clin Ther. 2009;31:213–219.
   PubMed Web of Science ®Google Scholar
• Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;16(2):CD000011.
   Google Scholar
• Hooper P, Tincello DG, Richmond DH. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study. Br J Urol. 1997;80(3):414–416.
   PubMedGoogle Scholar
• Trocio JN, Brubaker L, Schabert VF, et al. Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians. Postgrad Med. 2014;126(3):246–256.
   PubMed Web of Science ®Google Scholar
• Sung HH, Han DH, Kim TH, et al. Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial. Int J Clin Pract. 2015;69(11):1309–1315.
   PubMed Web of Science ®Google Scholar
• Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119 Suppl 1) (4):S32–S37.
   PubMed Web of Science ®Google Scholar
• Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20(4):764–771.
   PubMed Web of Science ®Google Scholar
• Fischer MA, Choudhry NK, Brill G, et al. Trouble getting started: predictors of primary medication nonadherence. Am J Med. 2011;124(11):1081e1089–1022.
   Web of Science ®Google Scholar
• Shah NR, Hirsch AG, Zacker C, et al. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med. 2009;24(2):233–237.
   PubMed Web of Science ®Google Scholar
• Shah NR, Hirsch AG, Zacker C, et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392–396.
   PubMed Web of Science ®Google Scholar
• Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve medication adherence. Eur Heart J. 2011;32(3):264–268.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–539.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719.
   PubMed Web of Science ®Google Scholar
• Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;66(3):332–337.
   Google Scholar
• Cohn JA, Brown ET, Reynolds WS, et al. An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Ther Adv Urol. 2016;8(2):83–90.
   PubMedGoogle Scholar
• Conn VS, Ruppar TM, Chan KC, et al. Packaging interventions to increase medication adherence: systematic review and meta-analysis. Curr Med Res Opin. 2015;31(1):145–160.
   PubMed Web of Science ®Google Scholar
• Paterson M, Kinnear M, Bond C, et al. A systematic review of electronic multi-compartment medication devices with reminder systems for improving adherence to self-administered medications. Int J Pharm Pract. 2016 Feb 1. doi:10.1111/ijpp.12242.
   PubMedGoogle Scholar
• Devi BR, Syed-Abdul S, Kumar A, et al. mHealth: an updated systematic review with a focus on HIV/AIDS and tuberculosis long term management using mobile phones. Comput Methods Programs Biomed. 2015;122(2):257–265.
   PubMed Web of Science ®Google Scholar
• Bemelmans R, Gelderblom GJ, Jonker P, et al. Socially assistive robots in elderly care: a systematic review into effects and effectiveness. J Am Med Dir Assoc. 2012;13(2):114–120 e111.
   PubMed Web of Science ®Google Scholar
• Lapane KL, Dube CE, Schneider KL, et al. Misperceptions of patients vs providers regarding medication-related communication issues. Am J Manag Care. 2007;13(11):613–618.
   PubMed Web of Science ®Google Scholar
• Carpenter DM, Elstad EA, Blalock SJ, et al. Conflicting medication information: prevalence, sources, and relationship to medication adherence. J Health Commun. 2014;19(1):67–81.
   PubMed Web of Science ®Google Scholar
• Miller TA. Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis. Patient Educ Couns. 2016;99(7):1079–1086.
   PubMed Web of Science ®Google Scholar
• Mayberry LS, Osborn CY. Family support, medication adherence, and glycemic control among adults with type 2 diabetes. Diabetes Care. 2012;35(6):1239–1245.
   PubMed Web of Science ®Google Scholar